Five Prime Therapeutics, Inc. FPRX

Five Prime Therapeutics, Inc. General and Administrative Expenses 2011-2026 | FPRX

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Five Prime Therapeutics, Inc.

2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
40.6 M	42.7 M	39.7 M	40 M	35.8 M	22.6 M	13.6 M	10.4 M	9.01 M	11.2 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
42.7 M	9.01 M	26.6 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	10.9 M	-	10.36 %	$ 9.8 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
Avenue Therapeutics ATXI	3.65 M	-	-52.27 %	$ 4.45 M	USA
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Axcella Health AXLA	15.8 M	-	-16.42 %	$ 249 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	166 M	-	-	$ 546 M	USA
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
Brickell Biotech BBI	11.2 M	-	-5.38 %	$ 6.06 M	USA
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA
CASI Pharmaceuticals CASI	23.8 M	-	-	$ 35.4 M	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
ChemoCentryx CCXI	78.9 M	-	-	$ 3.74 B	USA
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Завод ДИОД DIOD	19.7 M	-	-	-	Russia
Фармсинтез LIFE	24.1 M	-	-	-	Russia
Bellerophon Therapeutics BLPH	6.02 M	-	-74.18 %	$ 955 K	USA
Chimerix CMRX	24.6 M	-	-	$ 756 M	USA
Teligent, Inc. TLGT	23.4 M	-	-13.85 %	$ 16.1 M	USA
AbbVie ABBV	14 B	$ 208.7	-0.07 %	$ 369 B	USA
Calithera Biosciences CALA	20.9 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	8.74 M	-	-3.03 %	$ 260 M	USA
Viela Bio, Inc. VIE	60.2 M	-	-	$ 2.91 B	USA
AbCellera Biologics ABCL	83.2 M	$ 3.52	-0.14 %	$ 1.05 B	Canada